ERBB2 and breast carcinoma: Ki67 scores are clinically relevant particularly for early-stage luminal/HER2-negative breast cancer in post-menopausal patients, whereas treatment choices for triple-negative and HER2-positive cancers are mostly independent of Ki67 [25].